- The use of an inhibitor of the activity of MGDG 1. product synthase, for preparing a medicinal against apicomplex parasites.
- The use as claimed in claim 1, characterized in 2. that said apicomplex parasite is selected from the Plasmodium, Toxoplasma and group consisting of Eimeria.
- The use of an inhibitor of the activity of MGDG 3. synthase, as a herbicide.
- Α screening and 4. method for for selecting antiparasitic and/or herbicides, agents characterized in that it \comprises:
 - incubating a substance to be tested with an MGDG synthase or with a plastidial membrane isolated from a plant and
 - -- measuring the specific enzymatifs activity, after said incubation.
- The method as claimed in claim 4, Characterized in 5. that said MGDG synthase preferably has an initial specific activity of between $\sqrt{0.1}$ and 120 μ mol of galactose incorporated/h/mg of protein.
- The method as claimed in claim 4 or claim 5, 6. characterized in that the MGDG synthase/substance to be tested incubation is carried out in an incubation medium containing a buffer adjusted to a pH of between 6 and 9, in the presence of detergents, οf а reducing agent, of phosphatidylglycerol and of a salt.

REPLACEMENT PAGE AMENDED SHEET

4 45. 12.3 76" 12.3 73.1 65. 65. 17.9 15.1 15.1 15.1 15.1 15

5

10

25

30

35

5

- 7. The method as claimed in claim 6, characterized in that the incubation medium preferably contains 50 mM of MOPS-NaOH, pH 7.8, 4.5 mM of CHAPS, 1 mM of DTT, 1.3 mM of phosphatidylglycerol, 250 mM of KH₂PO₄/K₂HPO₄ and 250 mM of KCl.
- 8. The method according to any one of claims 4 to 7, characterized in that the MGDG synthase is of plant origin and is selected from the group consisting of the purified or recombinant MGDG synthases A and MGDG synthases B.
- 9. The method as claimed in any one of claims 4 to 8,
 15 characterized in that said apicomplex parasite is selected from the group consisting of *Plasmodium*,

 Toxoplasma and Eimeria.
- 10. The use of an MGDG synthase inhibitor selected in accordance with the method as claimed in any one of claims 4 to 8, for producing a medicinal product against apicomplex parasites.
- 11. The use of an MGDG synthase inhibitor selected in accordance with the method as claimed in any one of claims 4 to 8, as a herbicide.

ADA

REPLACEMENT PAGE
AMENDED SHEET